tagraxofusp + venetoclax + azacitidine

Tagraxofusp + venetoclax + azacitidine is an investigational three-drug combination regimen under clinical evaluation for the treatment of adults with previously untreated CD123-positive acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. Tagraxofusp is a CD123-directed recombinant fusion protein combining human interleukin-3 and a truncated diphtheria toxin payload, causing targeted cytotoxicity to CD123-expressing cells. Venetoclax is a small molecule inhibitor of the anti-apoptotic protein BCL-2, leading to apoptosis of cancer cells dependent on BCL-2 for survival. Azacitidine is a DNA hypomethylating agent, restoring normal gene function by inhibiting DNA methylation and promoting differentiation or apoptosis of myeloid cells. The triplet regimen is synergistic, with azacitidine sensitizing AML cells to tagraxofusp, and tagraxofusp-exposed cells becoming more vulnerable to BCL-2 inhibition. Early-phase studies show encouraging efficacy and an acceptable safety profile in AML, including high-risk subpopulations such as those with TP53 mutations[3][4][5][6][7].

Brand names

Elzonris (tagraxofusp)Venclexta (venetoclax)Vidaza (azacitidine)

Other names

TAG + VEN + AZATAG-AZA-VENtagraxofusp/venetoclax/azacitidine